Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Group 1 - Kymera Therapeutics, Inc. announced a public offering of $250.8 million, selling 5,044,500 shares of common stock at $44.00 per share and pre-funded warrants at $43.9999 each [1][2] - The offering includes a 30-day option for underwriters to purchase an additional 855,000 shares at the public offering price [1] - The expected gross proceeds from the offering are approximately $250.8 million before deducting underwriting discounts and commissions [1][2] Group 2 - Kymera plans to use the net proceeds to advance its pipeline of preclinical and clinical degrader programs, targeting large patient populations with significant needs [2] - The company is recognized for pioneering targeted protein degradation (TPD) to develop innovative therapies for immunological diseases [6] - Founded in 2016, Kymera has been acknowledged as one of Boston's top workplaces in recent years [6]